Valeant Pharmaceuticals International Inc (VRX): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International ( VRX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.6%. By the end of trading, Valeant Pharmaceuticals International fell $1.94 (-1.9%) to $101.06 on average volume. Throughout the day, 1,547,908 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,904,200 shares. The stock ranged in price between $100.95-$103.21 after having opened the day at $102.79 as compared to the previous trading day's close of $103.00. Other companies within the Health Care sector that declined today were: GTx ( GTXI), down 65.5%, Mast Therapeutics ( MSTX), down 43.4%, Epizyme ( EPZM), down 14.1% and Stereotaxis ( STXS), down 12.7%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $34.2 billion and is part of the drugs industry. Shares are up 72.5% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 13.6%, Bovie Medical Corporation ( BVX), up 11.9%, Arrhythmia Research Technology ( HRT), up 11.7% and Genvec ( GNVC), up 11.1% , were all gainers within the health care sector with Allergan ( AGN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year